A matched-pair analysis comparing whole-brain radiotherapy with and without a stereotactic boost for intracerebral control and overall survival in patients with one to three cerebral metastases

Radiation Oncology

Volumn 12, Issue 1, 2017, Pages

  Rades, Dirk ^a   Janssen, Stefan ^a,b   Bajrovic, Amira ^c   Khoa, Mai Trong ^d   Veninga, Theo ^e   Schild, Steven E ^f  

^a UNIVERSITY OF LÜBECK   (Germany)

^b Gemeinschaftspraxis for Radiation Oncology and Radiotherapy   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d BACH MAI HOSPITAL   (Viet Nam)

^e DR BERNARD VERBEETEN INSTITUTE   (Netherlands)

^f MAYO CLINIC   (United States)

Author keywords

Cerebral metastases; Intracerebral control; Overall survival; Stereotactic boost; Whole brain radiotherapy

Indexed keywords

ADULT; AGE; ARTICLE; BRAIN METASTASIS; CANCER CONTROL; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENDER; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDIAN SURVIVAL TIME; MIDDLE AGED; OVERALL SURVIVAL; PRIMARY TUMOR; STEREOTACTIC RADIOSURGERY; TIME TO TREATMENT; WHOLE BRAIN RADIOTHERAPY; BRAIN TUMOR; MORTALITY; PROGNOSIS; RADIOTHERAPY DOSAGE; SECONDARY; SKULL IRRADIATION; STATISTICAL ANALYSIS; SURVIVAL RATE;

BRAIN NEOPLASMS; COHORT STUDIES; CRANIAL IRRADIATION; FEMALE; HUMANS; MALE; MATCHED-PAIR ANALYSIS; MIDDLE AGED; PROGNOSIS; RADIOTHERAPY DOSAGE; SURVIVAL RATE;

EID: 85018551239     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/s13014-017-0804-1     Document Type: Article

References (21)

1. Khuntia D, Brown P, Li J, Mehta MP. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol. 2006;24:1295-304.
2. Tsao MN, Rades D, Wirth A, Lo SS, Danielson BL, Gaspar LE, Sperduto PW, Vogelbaum MA, Radawski JD, Wang JZ, Gillin MT, Mohideen N, Hahn CA, Chang EL. Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol. 2012;2:210-25.
3. Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, Kenjyo M, Oya N, Hirota S, Shioura H, Kunieda E, Inomata T, Hayakawa K, Katoh N, Kobashi G. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases. A randomized controlled trial. JAMA. 2006;295:2483-91.
4. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10:1037-44.
5. Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, Baumert BG, Fariselli L, Tzuk-Shina T, Kortmann RD, Carrie C, Ben Hassel M, Kouri M, Valeinis E, van den Berge D, Collette S, Collette L, Mueller RP. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol. 2011;29:134-41.
6. Brown PD, Jaeckle K, Ballman KV, Farace E, Cerhan JH, Anderson SK, Carrero XW, Barker 2nd FG, Deming R, Burri SH, Ménard C, Chung C, Stieber VW, Pollock BE, Galanis E, Buckner JC, Asher AL. Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. JAMA. 2016;316:401-9.
7. Regine WF, Scott C, Murray K, Curran W. Neurocognitive outcome in brain metastases patients treated with accelerated-fractionation vs. accelerated-hyperfractionated radiotherapy: an analysis from Radiation Therapy Oncology Group Study 91-04. Int J Radiat Oncol Biol Phys. 2001;51:711-7.
8. Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, Illidge T, Kunkler I, Caudrelier JM, Eisenberg PD, Meerwaldt J, Siemers R, Carrie C, Gaspar LE, Curran W, Phan SC, Miller RA, Renschler MF. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. J Clin Oncol. 2004;22:157-65.
9. Aoyama H, Tago M, Kato N, Toyoda T, Kenjyo M, Hirota S, Shioura H, Inomata T, Kunieda E, Hayakawa K, Nakagawa K, Kobashi G, Shirato H. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int J Radiat Oncol Biol Phys. 2007;68:1388-95.
10. Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. Int J Radiat Oncol Biol Phys. 1999;45:427-34.
11. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, Werner-Wasik M, Demas W, Ryu J, Bahary JP, Souhami L, Rotman M, Mehta MP, Curran Jr WJ. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363:1665-72.
12. Kaplan EL, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-81.
13. Sahgal A, Aoyama H, Kocher M, Neupane B, Collette S, Tago M, Shaw P, Beyene J, Chang EL. Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis. Int J Radiat Oncol Biol Phys. 2015;91:710-7.
14. DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. Neurology. 1989;39:789-96.
15. Shaw MG, Ball DL. Treatment of brain metastases in lung cancer: strategies to avoid/reduce late complications of whole brain radiation therapy. Curr Treat Options Oncol. 2013;14:553-67.
16. Gondi V, Pugh SL, Tome WA, Caine C, Corn B, Kanner A, Rowley H, Kundapur V, DeNittis A, Greenspoon JN, Konski AA, Bauman GS, Shah S, Shi W, Wendland M, Kachnic L, Mehta MP. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial. J Clin Oncol. 2014;32:3810-6.
17. Huttenlocher S, Dziggel L, Hornung D, Blanck O, Schild SE, Rades D. A new prognostic instrument to predict the probability of developing new cerebral metastases after radiosurgery alone. Radiat Oncol. 2014;9:215.
18. Fogarty GB, Hong A, Gondi V, Burmeister B, Jacobsen K, Lo S, Paton E, Shivalingam B, Thompson JF. Debate: adjuvant whole brain radiotherapy or not? More data is the wiser choice. BMC Cancer. 2016;16:372.
19. Du Four S, Hong A, Chan M, Charakidis M, Duerinck J, Wilgenhof S, Wang W, Feng L, Michotte A, Okera M, Shivalingam B, Fogarty G, Kefford R, Neyns B. Symptomatic histologically proven necrosis of brain following stereotactic radiation and ipilimumab in six lesions in four melanoma patients. Case Rep Oncol Med. 2014;2014:417913.
20. Savitz ST, Chen TC, Sher DJ. Cost-effectiveness analysis of neurocognitive-sparing treatments for brain metastases. Cancer. 2015;121:4231-9.
21. Awad R, Fogarty G, Hong A, Kelly P, Ng D, Santos D, Haydu L. Hippocampal avoidance with volumetric modulated arc therapy in melanoma brain metastases - the first Australian experience. Radiat Oncol. 2013;8:62.